ADVOCACY IS AT THE HEART OF PATIENT CARE

Patients trust your knowledge and insights

In fact, nurses received the highest ethics rating—far more than any of the other 17 professions rated.1

79% of US adults said that nurses have “very high” or “high” levels of honesty and ethical standards1,*

  • *

    Results from a Gallup poll based on telephone interviews conducted from November 9 to December 2, 2022, with a random sample of 1020 adults, ≥18 years old, living in all 50 US states and the District of Columbia. Survey participants were asked “Please tell me how you would rate the honesty and ethical standards of people in these different fields—very high, high, average, low or very low?”1

Create Meaningful Connections

Each shingles experience is personal—that's why understanding risk factors, its impact, and its potential complications is so critical.

Female nurse using phone

Care with Confidence

The decision to vaccinate is important. Learn important facts about SHINGRIX so you feel confident in the discussion.

Male nurse writing

Lead the Conversation

Discover resources to strengthen your knowledge and to help guide the conversation with your patients.

Female nurse speaking

Shingles could have more of an impact than you realize

Shingles usually presents as a painful, unilateral, blistering rash that lasts 7 to 10 days and can take 2 to 4 weeks to heal.2

Patients may experience complications from shingles3,†

Postherpetic neuralgia (PHN)3

PHN affects 10% to 18% of patients with shingles. This nerve pain lingers for more than 90 days after the shingles rash and can persist for years.

Postherpetic neuralgia patient

Herpes zoster ophthalmicus (HZO)3

HZO affects 10% to 25% of patients with shingles. This can lead to ocular complications and, in rare cases, vision loss.

Herpes zoster ophthalmicus image
  • †

    SHINGRIX is not indicated for the prevention of PHN or other herpes zoster-related complications.4

Nearly everyone ≥50 years of age is at risk for shingles, no matter how healthy they feel.3,5

99.5 percent of people greater than or equal to 50 years old already are infected with the varicella zoster virus

In 1 out of 3 people,

the dormant virus reactivates in their lifetime and causes shingles3

Zoster virus incidence rate by age in the United States chart

Starting at 50 years old, shingles risk sharply increases3

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults ≥50 years old.4

CDC recommendations6,7:

SHINGRIX is recommended for the prevention of herpes zoster and related complications§ for immunocompetent adults ≥50 years old

  • SHINGRIX is recommended regardless of whether they report a prior dose of Zostavax, a shingles vaccine that is no longer available for use in the United States
  • It is not necessary to screen, either verbally or by laboratory serology, for evidence of prior varicella infection


Please visit CDC.gov for full routine shingles vaccination recommendations, including recommendations for immunocompromised adults.

  • §

    SHINGRIX is not indicated for the prevention of herpes zoster-related complications.4

Proven shingles protection

SHINGRIX delivered greater than 90 percent efficacy against shingles graphic

|| Data from the phase 3 ZOE-50 (≥50 years old) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years old from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.4,8

What you say matters

To communicate the importance of vaccination with SHINGRIX, follow a simple 3-step plan:

Step 1 icon

Educate patients on shingles2,3

Explain that shingles is a painful, blistering rash that can last 7 to 10 days and may lead to complications.Starting at 50 years old, shingles risk sharply increases.

Step 2 icon

Make the risk of shingles relatable

Personalize your recommendation by using pronouns such as “you” along with connecting to the patient’s age group. Share an experience of the impact shingles has had on your patients and the importance of vaccination.

Step 3 icon

Recommend SHINGRIX

Use actionable language to round out your recommendation, so it’s clear to the patient that your recommendation is coming from a place of protection. Set expectations by outlining potential vaccine side effects and creating a vaccination plan with your patients. 

  • SHINGRIX is not indicated for the prevention of herpes zoster-related complications.3

The best conversation starts with the right information

The following resources can be used to help turn each conversation into shingles prevention

Vaccine Scheduler
What to Expect Guide
Strong Recommendation Discussion Guide

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or
1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Brenan M. Nurses Retain Top Ethics Rating in US, but Below 2020 High. Gallup. January 10, 2023. https://news.gallup.com/poll/467804/nurses-retain-top-ethics-rating-below-2020-high.aspx
  2. Shingles symptoms and complications. Centers for Disease Control and Prevention. April 19, 2024. Accessed May 21, 2024. https://www.cdc.gov/shingles/signs-symptoms/index.html
  3. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
  4. Prescribing Information for SHINGRIX.
  5. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl1):S111-S118.
  6. SHINGRIX recommendations. Centers for Disease Control and Prevention. Reviewed January 24, 2022. Accessed February 9, 2024. https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html
  7. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103-108.
  8. Data on file. Study 113077 (NCT01165229). GSK Study Register. Study entry at: https://www.gskstudyregister.com/en/trial-details/?id=113077.

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET